Indivior Set to Engage Investors in Key Upcoming Events Across the U.S.

Indivior PLC, listed on NASDAQ and LSE under the ticker INDV, has made an exciting announcement regarding its participation in a series of investor events slated for June 2025. This initiative shows the company’s commitment to form connections with their investor community and share insights on their future directions and aspirations in the healthcare landscape.

Event Highlights

The first significant event on the calendar is the Jefferies Global Healthcare Conference, taking place in New York City, NY on June 4th. At this event, Joe Ciaffoni, CEO, and Ryan Preblick, CFO, will be hosting both one-on-one and group meetings, providing a platform for in-depth discussions regarding Indivior's plans and advances. Ciaffoni is also confirmed to engage in a special fireside chat, scheduled for 9:55 a.m. U.S. ET that day, which will be accessible publicly via a webcast. Interested investors are encouraged to reach out to their Jefferies representatives to secure their appointments.

Following this, on June 11th, Indivior will be present at the Goldman Sachs 46th Annual Global Healthcare Conference in Miami, FL. Again, Ciaffoni and Preblick will host meeting sessions throughout the day. Investors wishing to participate are invited to coordinate through their Goldman Sachs contacts.

The final event in this series is the Northland Growth Conference 2025, which is set to occur virtually on June 25th. Ciaffoni and Preblick will continue to engage with investors through virtual meetings, an increasingly valued approach in today’s digital environment. Potential attendees should confer with their Northland representatives to organize a meeting.

About Indivior

Indivior has positioned itself as a leading global pharmaceutical company, dedicated to addressing substance use disorders (SUD) and enhancing patient well-being. With a vision to make evidence-based treatments accessible globally, Indivior's commitment is reflected in its ongoing research and development efforts aimed at transforming SUD from a stigma-ridden issue into a recognized chronic malady that can be effectively treated.

The company is building on its strong portfolio of medications designed for opioid use disorders (OUD) and has an extensive pipeline of new product candidates poised to expand its reach within this essential healthcare sector. Headquartered in Richmond, VA, Indivior operates across more than 30 countries, employing over 1,000 individuals dedicated to the mission of changing lives through better healthcare solutions.

For those interested in learning more about Indivior and their contributions to the world of pharmaceutical treatments for SUD, visit their website at www.indivior.com. Stay connected by following them on LinkedIn at linkedin.com/company/indivior.

Conclusion

Indivior’s active engagement in these investor events underscores the company’s strategic approach to maintaining transparency and fostering relationships with its stakeholders. As the pharmaceutical landscape continues to evolve, events like these are vital for investor understanding and collaboration in achieving better health outcomes worldwide.